So it appears that the failure of this product is not due to 510(k) process but to regulatory inaction by our own FDA.
Phil Gingrey: “So it appears that the failure of this product is not due to 510(k) process but to regulatory inaction by our own FDA.”
Editor's note · Context
Gingrey argues that regulatory inaction, not the 510(k) process, caused issues with medical devices.
Share
More from Phil Gingrey
Let me first commend Chairman Upton and our colleague from Colorado, Ms. DeGette, for spearheading this bipartisan endeavor.
I want to thank Chairman Murphy for holding the hearing, educating members of the subcommittee on the impact of the Obama Administration's continued, and make no mistake about it, war on coal is what it is, is having on local communities.
As educators and legislators, we must not neglect our duties to equip these young people, our children, these students, with the tools and the knowledge to build a successful career.
I assure you that there is a plan. There may be a few people in this town that want to pretend that there is no plan. But there is.





